Decisions on new HML products and restrictions changes

PHARMAC has made decisions for the following products, with the changes being effective from 5 July 2013:

**Defibrotide**
- The restriction applying to defibrotide injections will be amended as follows (deletions in strikethrough, additions in bold):

  Restricted – Haematologist
  Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities after allogeneic stem-cell transplantation.

**Edrophonium chloride**
- Another presentation of edrophonium chloride – inj 10 mg per ml, 15 ml vial, will be listed subject to the same restriction that currently applies to edrophonium chloride 10 mg per ml, 1 ml ampoule.

**Oestriol**
- There will be a correction to the naming of the medicine oestradiol tab 2mg, which should be oestriol tab 2mg in the Other Oestrogen Preparations subsection of the Hormone Preparations therapeutic group.

**Atovaquone with proguanil hydrochloride**
- A paediatric presentation of atovaquone with proguanil hydrochloride will be listed – atovaquone with proguanil hydrochloride tab 62.5 mg with proguanil hydrochloride 25 mg.
- This new presentation will be subject to the same restrictions as the atovaquone with proguanil hydrochloride tab 250 mg with proguanil hydrochloride 100mg presentation.

**Amendment to the restriction applying to immunisations**
- The restrictions currently applying to the following vaccines will be amended as follows (additions in bold):

  **Vaccines:**
  - Diphtheria and tetanus vaccine
  - Haemophilus influenzae type b vaccine
  - Pneumococcal conjugate (pcv13) vaccine
  - Pneumococcal (ppv23) polysaccharide vaccine
  - Diphtheria, tetanus, pertussis, polio, hepatitis b and haemophilus influenzae type b vaccine

  Restriction change:
  For revaccination of children following immunosuppression

**Sodium chloride nasal spray**
- The listing of sodium chloride nasal spray will be amended as follows (additions in bold, deletions in strikethrough):

  SODIUM CHLORIDE
Aqueous nasal spray 6.5 7.4 mg per ml

**Cabergoline**
- The restrictions applying to cabergoline will be amended as follows (additions in bold):

  **CABERGOLINE**
  Tab 0.5 mg
  Restricted
  Either:
  1. Inhibition of lactation
  2. Patient has pathological hyperprolactinemia
  3. Patient has acromegaly

**Bupivacaine**
- A larger bag size of bupivacaine hydrochloride will be listed – inj 1.25 mg per ml, 500 ml bag.